PUBLICATIONS PEER REVIEWED JOURNALS & BOOK CHAPTERS

2019

Rencuzoglu C, Cincin ZB, Iplik ES, Baran Y, Cakmakoglu B. Investigation of Potential Anticarcinogenic Effects of Corilagin in Lung Cancer Cells. Clinical and Experimental Health Sciences, 2019, 9 (3), 228-231.

2019

Baran Y*, Ulu GT, Kiraz Y. Role of Polyunsaturated Fatty Acids in Cancer and Their Use in Cancer Treatment. Reviews in Clinical Medicine, 2019, 6 (3), 84-90.

2019

Cox S, Rousseau-Tsangaris M, Abou-Zeid N, Dalle S, Leurent P, Cutivet A, Le HH, Kotb S, Bogaert B, Gardette R, Baran Y, Holder JM, Lerner L, Blay JY, Cambrosio A, Tredan O, Denèfle P*. Precision medicine in oncology: Challenges, stakes and new paradigms. Bull Cancer, 2019, 106(2):97-104.

2018

Gül Amuk N*, Kurt G, Kartal Yandim M, Adan A, Baran Y. A minimally invasive transfer method of mesenchymal stem cells to the intact periodontal ligament of rat teeth: A preliminary study. Turkish Journal of Biology, 2018; 42(5): 382-391.

2018

Baran Y*, Kiraz Y, Ulu GT. Kanser Moleküler Biyololisi, Kısayol Yayıncılık, 586 sayfa kitap, 2018.

2018

Iplik ES, Ertugrul B, Kozanoglu I, Baran Y, Cakmakoglu B*. An answer to colon cancer treatment by mesenchymal stem cell originated from adipose tissue. Iranian Journal of Basic Medical Sciences, 2018; 21 (5): 465.

2018

Cincin ZB, Kiran B, Baran Y, Cakmakoglu B. Hesperidin promotes programmed cell death by downregulation of nongenomic estrogen receptor signalling pathway in endometrial cancer cells. Biomed Pharmacother, 2018, 103: 336-345.

2017

Neergheen-Bhujun V, Awan AT, Baran Y, Bunnefeld N, Chan K, Dela Cruz TE, Egamberdieva D, Elsässer S, Johnson MV, Komai S, Konevega AL, Malone JH, Mason P, Nguon R, Piper R, Shrestha UB, Pešić M, Kagansky A. Biodiversity, drug discovery, and the future of global health: Introducing the biodiversity to biomedicine consortium, a call to action. J Glob Health, 2017; 7(2): 020304.

2017

Işık S, Uzuner N, Karaman M, Karaman Ö, Kıray M, Kozanoğlu İ, Alper Bağrıyanık H, Arıkan-Ayyıldız Z, Kartal Yandım M, Baran Y. Effects of Intraperitoneal Injection of Allogeneic Bone Marrow-derived Mesenchymal Stem Cells on Bronchiolitis Obliterans in Mice Model. Iran J Allergy Asthma Immunol, 2017; 16(3): 205-218.

2017

Ozer I, Tomak A, Zareie HM, Baran Y, Bulmus V*. Effect of Molecular Architecture on Cell Interactions and Stealth Properties of P Biomacromolecules, 2017;18(9): 2699-2710.

2017

Amuk NG, Kurt G, Baran Y*, Seyrantepe V, Kartal-Yandim M, Adan A, Sönmez MF. Effects of Cell-Mediated Osteoprotegerin Gene Transfer and Mesenchymal Stem Cell Applications on Orthodontically Induced Root Resorption of Rat Teeth, European Journal of Orthodontics 2017; 39(3):235-242.

2017

Işık S*,Uzuner N, Karaman M, Karaman Ö, Kıray M, Kozanoğlu İ, Bağrıyanık HA, Arıkan-Ayyıldız Z, Kartal Yandım M, Baran Y. Potent effects of mesenchymal stem cells on murine model of bronchiolitis obliterans. Iranian Journal of Allergy, Asthma and Immunology, 2017; 16(3), 205-218.

2017

Apohan E*, Yilmaz U, Yilmaz O, Serindag A, Kucukbay H, Yesilada O, Baran Y. Synthesis, Cytotoxic and Antimicrobial Activities of Novel Cobalt and Zinc Complexes of Benzimidazole Derivatives. Journal of Organometallic Chemistry, 2017; 828, 52-58.

2017

Işık S*, Karaman M, Adan A, Kıray M, Bağrıyanık HA, Sözmen ŞÇ, Kozanoğlu İ, Karaman Ö, Baran Y, Uzuner N. Intraperitoneal Mesenchymal Stem Cell Administration Ameliorates Allergic Rhinitis in the Murine Model. European Archives of Oto-Rhino-Laryngology and Head & Neck, 2017; 274, 197-207.

2016

Kiraz Y, Neergheen-Bhujun VS, Rummun N, Baran Y*. Apoptotic Effects Of Non-Edible Parts Of Punica Granatum On Human Multiple Myeloma Cells. Tumor Biology, 2016; 37(2): 1803-1815.

2016

Adan A, Kiraz Y, Baran Y*. Cell Proliferation And Cytotoxicity Assays. Current Pharmaceutical Biotechnology, 2016; 17(14): 1213-1221

2016

Adan A, Baran Y*. Fisetin and hesperetin induced apoptosis and cell cycle arrest in chronic myeloid leukemia cells accompanied by modulation of cellular signaling. Tumor Biology, 2016; 37(5): 5781-5795.

2016

Yandim MK, Ceylan C, Elmas E, Baran Y*. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib. Tumor Biology, 2016; 37(2): 2365-2378.

2016

Kiraz Y, Adan A, Kartal Yandim M, Baran Y*. Major apoptotic mechanisms and genes involved in apoptosis. Tumor Biology, 2016; 37(7): 8471-8476.

2016

Adan A, Alizada G, Kiraz Y, Nalbant A, Baran Y*. Flow cytometry: Basic principles and applications. Critical Reviews in Biotechnology, 2016; 14: 1-14.

2016

Nalbant A, Kiraz Y, Baran Y*. T cells in Tumor Microenvironment. Tumor Biology, 2016; 37 (1): 39-45

2015

Kartal Yandım M, Adan Gokbulut A, Baran Y*. Molecular Mechanisms of Drug Resistance and its Reversal in Cancer. Critical Reviews in Biotechnology, 2015; 24: 1-11.

2015

Kaymaz BT, Günel NS, Ceyhan M, Çetintaş VB, Özel B, Yandım MK, Kıpçak S, Aktan Ç, Gökbulut AA, Baran Y, Can BK. Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted Bhsa-miR-2278 as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A. Tumor Biology; 2015; 36(10): 7915-7927.

2015

Adan A, Baran Y*. The Pleiotropic Effects of Fisetin and Hesperetin on Human Acute Promyelocytic Leukemia Cells Are Mediated through Apoptosis, Cell Cycle Arrest and Alterations in Signaling Networks. Tumor Biology, 2015; 36(11): 8973-8984.

2015

Mutlu P, Kiraz Y, Gündüz U, BaranY*. An Update on Molecular Biology and Drug Resistance Mechanisms of Multiple Myeloma. Critical Reviews in Oncology/Hematology, 2015; 96(3): 413-424.

2015

Cincin ZB, Unlu M, Kiran B, Bireller ES, Kiraz Y, Baran Y, Cakmakoglu B*. Anti-proliferative, apoptotic and signal transduction effects of hesperidin in non-small cell lung cancer cells. Cellular Oncology, 2015; 38(3): 195-204.

2015

Katgı A, Sevindik OG, Gokbulut AA, Ozsan HG, Yuksel F, Solmaz SM, Alacacıoglu I, Ozcan MA, Demirkan F, Baran Y, Piskin O. Nilotinib Does Not Alter the Secretory Funcions of Carotid Artery Endothelıal Cells in a Prothrombotic or Antithrombotic Fashion. Clinical and Applied Thrombosis/Hemostasis, 2015; 21(7): 678-83.

2015

Gokbulut AA, Baran Y*. A Novel Natural Product, KL-21, Inhibits Proliferation and Induces Apoptosis in Chronic Lymphocytic Leukemia Cells. Turkish Journal of Hematology, 2015; 32(2): 118-26.

2015

Baran Y*. Drug Resistance in Cancer. Gunce, Official Journal of Turkish Academy of Sciences, 2015; 48: 67-70.

2015

Tufekçi O, Yandim MK, Oren H, Irken G, Baran Y*. Targeting FOXM1 Transcription Factor In Lymphoblastic Leukemia. Leukemia Research, 2015: 39(3); 342-347.

2015

Cincin ZB, Unlu M, Kıran B, Bireller ES, Baran Y*, Cakmakoglu B*. Apoptotic Effects of Quercitrin in DLD-1 Colon Cancer Cell Lines. Pathology and Oncology Research, 2015: 21; 333-338.

2014

Demirer T, Baran Y, Camcı, C, Olgun N, Ozcelik T, Ozet A, Ozkok S, Solak M, Zulfikar B, Gultekin M. National Cancer Policies Workshop Report. By Turkish Academy of Sciences, Cancer Research Group (Book).

2014

Ünlü M, Kiraz Y, Kacı FN, Ozcan MA, Baran Y*. Multidrug Resistance In Chronic Myeloid Leukemia. Turkish Journal of Biology, 2014 38(6); 806-816.

2014

Kiraz Y, Unlu M, Kartal Yandim M, Baran Y*. Molecular Biology of Stem Cells. Hematolog, 2014: 4(2); 255-265.

2014

Cincin ZB, Unlu M, Kıran B, Bireller ES, Baran Y*, Cakmakoglu B*. Molecular Mechanisms of Quercitrin-Induced Apoptosis in Non Small Cell Lung Cancer Cells. Archives of Medical Research, 2014; 45(6): 445-454.

2014

Omur O, Baran Y. An Update on Molecular Biology of Thyroid Cancers. Critical Reviews in Oncology/Hematology, 2014; 90(3): 233-252.

2014

Celikkanat D, Baran Y*. Comparative development of knowledge-based bioeconomy in the European Union and Turkey. Critical Reviews in Biotechnology, 2014; 34(3): 269-280.

2014

Solmaz S, Gokbulut AA, Cincin B, Ozdogu H, BogaC, Cakmakoglu B, Kozanoglu I, Baran Y*. Therapeutic Potential of Apigenin, a Plant Flavonoid, for Imatinib-Sensitive and Resistant Chronic Myeloid Leukemia Cells. Nutrition and Cancer; An International Journal, 2014; 66(4): 599-612.

2014

Aydemir LY, Adan Gokbulut A, Baran Y, Yemenicioglu A*. Bioactive, functional and edible film making properties of different protein isolates from Turkish hazelnut (Corylus avellana L.) meal obtained from oil extraction. Food Hydrocolloids, 2014; 36:130-142.

2014

Avci CB, Baran Y*. Micro RNAs in Personilized medicine. Methods in Molecular Biology; miRNomics: MicroRNA Biology and Computational Analysis, Humana Press, 2014, 1107:311-25

2014

Ömür Ö*, Baran Y, Oral A, Ceylan Y. Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography For Extranodal Staging Of Non-Hodgkin Lymphoma And Hodgkin Disease. Diagnostic and Interventional Radiology 2014;0(2):185-192.

2013

Yilmaz AF, Saydam G, Sahin F, Baran Y*. Granulocytic Sarcoma: A Systematic Review. American Journal of Blood Research, 2013; 3(4):265-270.

2013

Comert M, Baran Y*, Saydam G. Changes in moleculer biology of Chronic Myeloid Leukemia in Tyrosine Kinase Inhibitor era. 2013; (3):191-200. American Journal of Blood Research.

2013

Can G, Akpinar B, Baran Y, Zhivotovsky B, Olsson M*. 5-Fluouracil signaling through a calcium-calmodulin-dependent pathway is required for p53 activation and apoptosis in colon carcinoma cells. Oncogene, 2013; 32(38):4529-4538.

2013

Kiper HD, Tezcanli B, Gokbulut AA, Selvi N, Avci CB, Kosova BK, Iskender G, Yandım MK, Gunduz C, Sahin F, Baran Y*, Saydam STAT pathway in the regulation of zoledronic acid-induced apoptosis in chronic myeloid leukemia cells. Biomedicine and Pharmacotherapy, 2013; 67(6):527-532.

2013

Bozkurt S, Özkan T, Özmen F, Baran Y, Sunguroğlu A, Kansu E. The roles of epigenetic modifications of proapoptotic BID and BIM genes in imatinib-resistant chronic myeloid leukemia cells. Hematology, 2013, 18(4): 217-223.

2013

Gokbulut AA, Apohan E, Baran Y*. Resveratrol and quercetin induced apoptosis of human 232B4 chronic lymphocytic leukemia cells by activation of caspase-3 and cell cycle arrest. Hematology, 2013; 18(3):144-50.

2013

Firatligil B, Avci CB, Baran Y*. mir-17 in Imatinib Resistance and Response to Tryosine Kinase Inhibitors in Chronic Myeloid Leukemia Cells. J. BUON, 2013; 18(2):437-441.

2013

Sunay O, Can G, Cakir Z, Denek Z, Kozanoğlu I, Erdil G, Mustafa M, Baran Y*. Autologous Rabbit Adipose Tissue Derived Mesenchymal Stem Cells For The Treatment Of Bone Injuries With Distraction Osteogenesis. Cytotherapy, 2013; 15(6): 690-702.

2013

Camgoz A, Gencer EB, Ural AU, Baran Y*. Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance. Leukemia and Lymphoma, 2013; 54(6): 1279-1287.

2013

Turan T, Sanlı-Mohamed G*, Baran Y*. Changes in Protein Profiles of Multiple Myeloma Cells in Response to Bortezomib. Leukemia and Lymphoma, 2013; 54(5): 1061-1068.

2013

Senarisoy M, Canturk P, Zencir S, Baran Y, Topcu Z*. Gossypol interferes with both type I and type II topoisomerases activities without generating strand breaks. Cell Biochemistry and Biophysics, 2013; 66(1): 199-204.

2013

Baran Y*, Ceylan C, Camgoz A. The roles of macromolecules in imatinib resistance of chronic myeloid leukemia cells by Fourier transform infrared spectroscopy. Biomedicine and Pharmacotherapy, 2013; 67: 221-227.

2013

Kaymaz BT, Selvi N, Adan Gokbulut A, Aktan Ç, Gündüz C, Saydam G, Şahin F, Çetintaş VB, Baran Y, Kosova B*. Suppression of STAT5A and STAT5B Chronic Myeloid Leukemia Cells via siRNA and Antisense-Oligonucleotide Applications with the Induction of Apoptosis. American Journal of Blood Research, 2013; 3(1): 58-70.

2013

Kozanoglu I, Yandim MK, Cincin ZB, OzdoguH, Cakmakoglu B, Baran Y*. New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma. Journal of Cancer Research and Clinical Oncology. 2013; 139(2): 327-335.

2013

Yandım MK, Apohan E, Baran Y*. Therapeutic Potential of Targeting Ceramide/Glucosylceramide Pathway in Cancer. Cancer Chemotherapy and Pharmacology, 2013; 71(1): 13-20.

2013

Gokbulut AA, Yandım MK, Iskender G, Baran Y*. Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer. Current Medicinal Chemistry, 2013; 20: 108-122.

2012

Kozanoğlu İ*, Baran Y. The use of molecular diagnostic methods in hematology laboratory. Turkish Clinics, J Hem Onc-Special Topics, 2012; 5(4): 87-93.

2012

Bozcuk H, Abali H, Coskun S, Aydıner A, Çinkaya A, Demirkazık A, Özet A, Yolcu A, Balkan A, Çavdar A, Kefeli AÜ, Uluç BO, Atasoy B, Demirkan B, Yalçın B, Eroğlu C, Yalman D, Kılıç D, Tunalı D, Fırat D, Seber E, Üçgül Çavuşoğlu E, Ulukaya E, Kaytan Sağlam E, Tezcanlı E, Eryılmaz E, Dinçbaş FÖ, Telli F, Yumuk F, Başaran G, Çağlar HB, Sönmez H, Yılmaz H, Engin H, Helvacı K, Sönmez K, Koral L, Artaç M, Fuat Eren M, Koçar M, Beyzadeoğlu M, Akın M, Benekli M, Cengiz M, Erman M, Yıldız M, Doğan M, Balkan M, Eraktuğ N, Ünal OÜ, Şencan O, Erpolat Ö, Saip P, Kılıçkap S, Selçuk Seber SO, Paydaş S, Sarıhan S, Kömürcü Ş, Demirkasımoğlu T, Korkmaz T, Yetişyiğit T, Yavuzşen T, Evrensel T, Akman T, Abacıoğlu U, Kefeli U, Egeli Ü, Elgin Y, Baran Y, Bulut Z (Alphabetical order). The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis. World Journal of Surgical Oncology, 2012; 10(1): 161-167.

2012

Baran Y*, Saydam G. Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia. Journal of Blood Medicine, 2012; 3: 139–150.

2012

Can G, Cakir Z, Kartal M, Gunduz U, Baran Y*. Apoptotic Effects of Resveratrol, a Grape Polyphenol, on Imatinib Sensitive and Resistant K562 Cronic Myeloid Leukemia Cells. Anticancer Research, 2012; 32(7): 2673-8.

2012

Ceylan C, Camgoz A, Baran Y*. Macromolecular changes in nilotinib resistant K562 cells; an in vitro study by Fourier transform infrared spectroscopy. Technology in Cancer Research & Treatment, 2012; 11(4): 333-344.

2012

Purclutepe O, Iskender G, Kiper HD, Tezcanli B, Selvi N, Avci CB, Kosova B, Sahin F, Baran Y*, Saydam G. Enalapril-Induced Apoptosis of Acute Promyeloctic Leukemia Cells Involves STAT5A. Anticancer Research, 2012; 32: 2885-2894.

2012

Bassoy EY and Baran Y*. Bioactive Sphingolipids in Docetaxel-Induced Apoptosis in Human Prostate Cancer Cells. Biomedicine And Pharmacotherapy, 2012; 66(2): 103-110.

2012

Ekiz HA, Can G, Baran Y*. Role of autophagy in the progression and suppression of leukemias. Critical Reviews in Hematology/Oncology, 2012; 81(3): 275-285.

2011

Gucluler G, Piskin O, Baran Y*. The roles of antiapoptotic sphingosine kinase-1 and glucosylceramide genes in drug induced cell death of MCF-7 breast cancer cells. J BUON, 2011; 16(4): 646-651.

2011

Baran Y*. Gen Transfer Techniques in Cell Death Research. 2011, Book Chapter, Cell Death Research Methods Course, ISBN: 978-975-441-349-6.

2011

Baran Y*. Critical Decision of the Cell; Survive or Die. 2011, Book Chapter, Cell Death Research Methods Course, ISBN: 978-975-441-349-6.

2011

Adan A, Kartal M, Baran Y*. Molecular Biology of Breast Cancer. 2011, Book Chapter, Molecular Approaches to Breast Cancer, ISBN: 978-975-483-928-9.

2011

Baran Y, Zencir S, Çakır Z, Öztürk E, Topçu Z*.  Imatinib-induced apoptosis; A possible link to topoisomerase enzyme inhibition. Journal of Clinical Pharmacy and Therapeutics, 2011; 36(6): 673-679.

2011

Avcu F, Avcu N*, Er N, Kansu Ö, Baran Y, Pekel A, Ural AU. The Cytotoxic and Apoptotic-Necrotic Effects of Whitening Materials on Human Gingival Fibroblasts. Clinical Dentistry and Research, 2011; 35(1): 3-11.

2011

Gencer EB, Ural AU, Avcu F, Baran Y*. A novel mechanism of dasatinib-induced apoptosis in chronic myeloid leukemia; ceramide synthase and ceramide clearance genes. Annals of Hematology, 2011; 90(11): 1265-1275.

2011

Baran Y*, Bielawski J, Gunduz U, Ogretmen B. Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation. Journal of Cancer Research and Clinical Oncology, 2011; 137(10): 1535-1544.

2011

Avcı ÇB, Yılmaz S, Dogan ZO, Saydam G, Dodurga Y, Ekiz HA, Kartal M, Sahin F, Baran Y*, Gunduz C. Quercetin-induced Apoptosis involves increased HTERT enzyme activity of Leukemic Cells. Hematology, 2011; 16(5): 303-307.

2011

Firinci F*, Karaman M, Baran Y, Bagriyanik A, Ayyildiz ZA, Kiray M, Kozanoglu I, Yilmaz O, Uzuner N, Karaman O. Mesenchymal Stem Cells Ameliorate The Histopathological Changes in a Murine Model of Chronic Asthma. International Immunopharmacology, 2011; 11(8): 1120-1126.

2011

Camgoz A, Gencer EB, Ural AU, Avcu F, Baran Y*. Roles of ceramide synthase and ceramide clearence genes in nilotinib-induced cell death in chronic myeloid leukemia cells. Leukemia and Lymphoma, 2011; 52(8): 1574-84.

2011

Ekiz HA, Baran Y*. Bioactive Sphingolipids in Response to Chemotherapy: A Scope on Leukemias. Anti-Cancer Agents in Medicinal Chemistry, 2011; 11: 385-397.

2011

Salas A, Ponnusamy S, Senkal CE, Meyers MA, Selvam SP, Saddoughi SA, Apohan E, Sentelle RD, Smith C, Gault CR, Obeid LM, El-Shewy HM, Oaks J, Ramasamy S, Marcucci G, Baran Y, Mahajan S, Fernandes D, Stuart RK, Perrotti D, Ogretmen B*. : Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood, 2011; 117(22): 5941-5952.

2011

Mutlu P, Baran Y, Ural AU, Avcu F, Dirican B, Beyzadeoglu M, Gündüz U*. Effect Of Cobalt-60 (Γ Radiation) On Multidrug Resistant Multiple Myeloma Cell Lines. Cell Biology International, 2011; 35(7): 721-5.

2011

Sanli MG, Turan T, Ekiz HA, Baran Y*. The importance of protein profiling in the diagnosis and treatment of hematologic malignancies. Turkish Journal of Hematology, 2011; 28: 1-14.

2011

Kartal M, Saydam G, Sahin, Baran Y*. Resveratrol triggers apoptosis through regulating ceramide metabolizing genes in human K562 chronic myeloid leukemia cells. Nutrition and Cancer; An International Journal, 2011; 63(4): 637-644.

2011

Can G, Ekiz A, Baran Y*. Imatinib induces autophagy through BECLIN-1 and ATG5 genes in chronic myeloid leukemia cells. Hematology, 2011; 16(2): 95-99.

2011

Avcı CB, Gunduz C, Baran Y, Sahin F, Yilmaz S, Dogan ZO, Saydam G*. Caffeic Acid Phenethyl Esther Triggers Apoptosis Through Induction of Loss of Mitochondrial Membrane Potential in CCRF-CEM. Journal of Cancer Research and Clinical Oncology, 2011; 137: 41-47.

2011

Cakir Z, Saydam G, Sahin F, Baran Y*. The Roles Of Bioactive Sphingolipids In Resveratrol-Induced Apoptosis In HL60 Acute Myeloid Leukemia Cells. Journal Of Cancer Research And Clinical Oncology, 2011; 137: 279–286.

2010

Kosova B, Tezcanli B, Ekiz HA, Cakir Z, Selvi N, Dalmizrak A, Kartal M, Gunduz U, Baran Y*. Suppression of STAT5A increases chemotherapeutic sensitivity in imatinib-resistant and imatinib-sensitive K562 cells. Leukemia and Lymphoma, 2010; 51(10): 1895-901.

2010

Ekiz HA, Baran Y*. Therapeutic Applications of Bioactive Sphingolipids in Hematological Malignancies. International Journal of Cancer, 2010; 127(7): 1497-506.

2010

Baran Y*, Oztekin C, Bassoy EY. Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myleloid leukemia cells. Cancer Investigation, 2010; 28(6): 623-628.

2010

Goktas S, Baran Y, Ural AU, Yazici S*, Aydur E, Basal S, Avcu F, Pekel A, Dirican B, Beyzadeoglu M. Proteasome Inhibitor Bortezomib Increases Radiation Sensitivity in Androgen Independent Human Prostate Cancer Cells. Urology, 2010; 75(4): 793-798.

2010

Ekiz A, Can G, Gunduz U, Baran Y*. Nilotinib significantly induces apoptosis in imatinib-resistant K562 cells with wild-type BCR-ABL, as effectively as in parental sensitive counterparts. Hematology, 2010; 15(1): 33-38.

2009

Baran Y*, Oztekin C, Bassoy EY. Inhibition of Proteasome by Bortezomib Increased Chemosensitivity of BCR/ABL Positive Human K562 Chronic Myleoid Leukemia Cells to Imatinib. Health, 2009; 1(4): 320-324.

2009

Gucluler G, Baran Y*. Docetaxel Enhances the Cytotoxic Effects of Imatinib on Philadelphia Positive Human Chronic Myeloid Leukemia Cells. Hematology, 2009; 14(3): 139-144.

2009

Karabulut B, Erten C, Gul MK, Cengiz E, Karaca B, Kucukzeybek Y, Gorumlu G, Atmaca H, Uzunoglu S, Sanli Ua, Baran Y, Uslu R*. Docetaxel/Zoledronic Acid Combination Triggers Apoptosis Synergistically Through Downregulating Antiapoptotic Bcl-2 Protein Level In Hormone-Refractory Prostate Cancer Cells. Cell Biology International, 2009; 33(2): 239-246.

2009

Abaan DO, Mutlu PK, Baran Y, Atalay MC, Gunduz U*. Multidrug Resistance Mediated by MRP1 Gene Overexpression in Breast Cancer Patients. Cancer Investigation, 2009; 27(2): 201-205.

2008

Ural AU*, Avcu F, Baran Y. Bisphosphonate treatment and radiotherapy in metastatic breast cancer. Medical Oncology, 2008; 25(3): 350-355.

2008

Baran Y*, Ural AU, Avcu F, Sarper M, Elçi P, Pekel A. Optimization of Transfection of Green Fluorescent Protein in Pursuing Mesenchymal Stem Cells, In Vivo. Turkish Journal of Hematology, 2008; 25(4): 172-175.

2008

Avcu F, Ural AU, Sarper M, Uyuklu T, Baran Y, Safali M, Elçi P. The effects of proteasome inhibitor bortezomib on osteoblast differentiation of human bone marrow derived multipotent mesenchymal stem cells, In Vitro. 14th Annual International Society for Cellular Therapy Meeting, May 17-20 2008, Miami, Florida, USA, p.55.

2007

Baran Y, Salas A, Senkal CE, Gunduz U, Bielawski J, Obeid LM, Ogretmen B*. Alterations of Ceramide/Sphingosine 1-Phosphate Rheostat Involved in the Regulation of Resistance to Imatinib-induced Apoptosis in K562 Human Chronic Myeloid Leukemia Cells. Journal of Biological Chemistry, 2007; 282(15): 10922-10934.

2007

Baran Y*, Ural AU, Gunduz U. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells. Hematology, 2007; 12(6): 497-503.

2007

Baran Y*, Gur B, Kaya P, Ural AU, Avcu F, Gunduz U. Upregulation of multidrug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance. Hematology, 2007; 12(6): 511-517.

2007

Baran Y*, Gunduz U. Kronik Miyelositer Lösemi Genetiği (Genetics of chronic myeloid leukemia). Journal of Turkish Internal Medicine, 2007; 3(2): 50-55

2007

Ural AU*, Avcu F, Baran Y. Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer, 2007; 110(2): 469-470.

2007

Gorduysus M*, Avcu N, Gorduysus O, Pekel A, Baran Y, Avcu F, Ural AU. Cytotoxic Effects of Four Different Endodontic Materials in Human Periodontal Ligament Fibroblasts. Journal of Endodontics, 2007; 33(12): 1450-1454.

2006

Baran Y*, Gunduz U, Ural AU. Cross-resistance to cytosine arabinoside in human acute myeloid leukemia cells selected for resistance to vincristine. Experimental Oncology, 2006; 28(2): 163-165.

2005

Önalan G*, Selam B, Baran Y, Cincik M, Onalan R, Gündüz U, Ural AU, Pabuççu R. Serum and follicular fluid levels of soluble Fas, soluble Fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF. Human Reproduction, 2005; 20(9): 2391-2395.

2005

Baran Y*, Gündüz U, Ural AU. Expression of multidrug resistance (MDR1) gene in human promyelocytic leukemia cell line selected with vincristine. Turkish Journal of Cancer, 2005; 35(2): 88-92.

2018

BOOK

Cox S, Rousseau-Tsangaris M, Abou-Zeid N, Dalle S, Leurent P, Cutivet A, Le HH, Kotb S, Bogaert B, Gardette R, Baran Y, Holder JM, Lerner L, Blay JY, Cambrosio A, Tredan O, Denèfle P*. Precision medicine in oncology: Challenges, stakes and new paradigms. Bull Cancer. 2019 Feb;106(2):97-104.

*Corresponding Author